Heart Failure
News
FDA approves new type 2 diabetes drug bexagliflozin
Another SGLT2 inhibitor has been approved for type 2 diabetes based on results from 23 clinical trials in 5,000 patients.
Commentary
Damar Hamlin’s cardiac arrest: Key lessons
The goal of this discussion is to describe a systematic approach to evaluation and management of an athlete suffering blunt force chest and neck...
From the Journals
Emotional eating tied to risk of diastolic dysfunction
Cardiovascular disease prevention should include emotional regulation education, researchers suggest.
From the Journals
Simulation-based training effective for transesophageal echo
Cardiology fellows who learned transesophageal echocardiography using simulations scored higher on both theoretical and practical tests than those...
Conference Coverage
Atrial failure or insufficiency: A new syndrome
The syndrome may explain heart failure in patients with preserved pump function, according to researchers.
From the Journals
PPI use in type 2 diabetes links with cardiovascular events
Prospective data from almost 20,000 people with type 2 diabetes show that proton pump inhibitor use is linked with significantly more...
From the Journals
Frail ADHF patients benefit more from early rehab
Patients with acute decompensated heart failure who were frail at baseline benefited more from early targeted physical rehabilitation than those...
Commentary
Atrial fibrillation: Sex differences and modifiable risk factors
Experts examine to what extent greater height explains the differences in AF risk between men and women.
From the Journals
Top cardiology societies call for revamp of clinical trials
Clinical trials have become too costly and burdensome, and it’s time to reinvent how they are conducted, leading cardiology societies say in a...
From the Journals
Endocarditis tied to drug use on the rise, spiked during COVID
The steepest rise of infective endocarditis in people with cocaine/opioid use disorder occurred during the pandemic, suggesting COVID itself may...
Conference Coverage
Black HFrEF patients get more empagliflozin benefit in EMPEROR analyses
Empagliflozin trial data in patients with heart failure with reduced ejection fraction signal more benefit in Black, compared with White patients...